{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:10:07Z","timestamp":1793387407592,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21173"],"award-info":[{"award-number":["21173"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21754"],"award-info":[{"award-number":["21754"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21755"],"award-info":[{"award-number":["21755"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004248","name":"Psoriasis and Psoriatic Arthritis Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinthera.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:22:29Z","timestamp":1738786949000},"page":"293-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.005_bib0001","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0002","unstructured":"European Medicines Agency. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots [Internet]. 2020 [cited 2024 Sep 20];Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/xeljanz-article-20-procedure-ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots_en.pdf."},{"key":"10.1016\/j.clinthera.2025.01.005_bib0003","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors [Internet]. 2021 [cited 2024 Sep 20];Available from: https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-xeljanz-tofacitinib-increased-risk-major-adverse_en.pdf."},{"key":"10.1016\/j.clinthera.2025.01.005_bib0004","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [Internet]. 2022 [cited 2024 Sep 20];Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic."},{"key":"10.1016\/j.clinthera.2025.01.005_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.rdc.2020.04.001","article-title":"Risk of malignancy in spondyloarthritis: a systematic review","volume":"46","author":"Karmacharya","year":"2020","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0006","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0007","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40744-021-00407-8","article-title":"Comparison of clinical manifestations in rheumatoid arthritis vs. Spondyloarthritis: a systematic literature review","volume":"9","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0008","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/acr2.11601","article-title":"Tofacitinib efficacy and safety in patients with ankylosing spondylitis by prior biologic disease-modifying antirheumatic drug use: a post hoc analysis","volume":"5","author":"Deodhar","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","article-title":"Safety profile of Upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials","volume":"11","author":"Burmester","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0011","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/ard-2023-225271","article-title":"Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry","volume":"83","author":"Hern\u00e1ndez-Cruz","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0013","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0014","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0016","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/rheumatology\/kead531","article-title":"Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population","volume":"63","author":"Popa","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003630","article-title":"Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0019","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2023045","article-title":"Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data","volume":"45","author":"Min","year":"2023","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0020","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2023-eular.660","article-title":"Op0219 Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Jak-inhibitors compared to bdmards: data from an international collaboration of registries (the \u201cJak-Pot\u201d Study)","volume":"82","author":"Aymon","year":"2023","journal-title":"Ann Rheumat Dis"},{"key":"10.1016\/j.clinthera.2025.01.005_bib0022","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/bjd\/ljad229","article-title":"Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis","volume":"189","author":"Ertus","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:22:21Z","timestamp":1741684941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0149291825000074"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}